Melexis: update on the share buy-back program Press release - Regulated Information Ieper, Belgium – 23 June 2025, 17.45 hrs CET Further to the initiation of the share buy-back program announced on 10 December 2024, Melexis reports there were no purchases of Melexis shares on Euronext Brussels in the period from 16 to 20 June 2025. Trade dateTotal shares purchasedAverage price (€)Min price (€)Max price (€)Buyback amount (€)16/6/20250----17/6/20250----18/6/20250----19/6/20250----20/6/20250----TOTAL0---- As a result of purchases made since the launch of the share buy-back program for up t...
Melexis: update over het aandeleninkoopprogramma Persbericht - Gereglementeerde informatie Ieper, België – 23 juni 2025, 17.45 uur CET Naar aanleiding van het aandeleninkoopprogramma dat op 10 december 2024 werd aangekondigd, maakt Melexis bekend dat er geen eigen aandelen ingekocht werden op Euronext Brussel tussen 16 en 20 juni 2025. InkoopdatumAantal verworven aandelenGemiddelde prijs (€)Laagste prijs (€)Hoogste prijs (€)Aankoop bedrag (€)16/6/20250----17/6/20250----18/6/20250----19/6/20250----20/6/20250----TOTAAL0---- Als gevolg van aankopen die zijn gedaan sinds de lancering van he...
Hyloris announced the signing of an R&D funding agreement of $ 2m (plus $ 1.6m equity investment) with Kuvatris to support the development and US approval of intravenous (IV) suramin to treat human African trypanosomiasis (HAT). Given the rare nature of HAT, the value of this program lies in its potential to secure a transferable PRV. Recent examples show PRVs being sold for $160m – Hyloris could get just over 50% of net proceeds, if successful. We see this as a creative deal to boost the compan...
Melexis: update on the share buy-back program Press release - Regulated Information Ieper, Belgium – 16 June 2025, 17.45 hrs CET Further to the initiation of the share buy-back program announced on 10 December 2024, Melexis reports the purchase of 2,624 Melexis shares on Euronext Brussels in the period from 9 to 13 June 2025. Trade dateTotal shares purchasedAverage price (€)Min price (€)Max price (€)Buyback amount (€)9/6/20251,97264.7164.3565.00127,61410/6/20250----11/6/20250----12/6/20250----13/6/202565265.0065.0065.0042,380TOTAL2,62464.7864.3565.00169,994 As a result of purchases made...
Melexis: update over het aandeleninkoopprogramma Persbericht - Gereglementeerde informatie Ieper, België – 16 juni 2025, 17.45 uur CET Naar aanleiding van het aandeleninkoopprogramma dat op 10 december 2024 werd aangekondigd, maakt Melexis bekend dat er 2.624 eigen aandelen ingekocht werden op Euronext Brussel tussen 9 en 13 juni 2025. InkoopdatumAantal verworven aandelenGemiddelde prijs (€)Laagste prijs (€)Hoogste prijs (€)Aankoop bedrag (€)9/6/20251.97264,7164,3565,00127.61410/6/20250----11/6/20250----12/6/20250----13/6/202565265,0065,0065,0042.380TOTAAL2.62464,7864,3565,00169.994 Als...
In general, a weaker USD has a negative impact on Benelux stocks, particularly for companies with significant exports to the US. In this note we selected a list of companies with high US export exposure and we examine the potential impact on FY25 earninings. On top of the weak dollar, rising trade tensions or the introduction of tariffs further harm Benelux exporters. As the dollar depreciates against the euro, European goods become costlier for American consumers. At the same time, revenues ear...
Melexis: update over het aandeleninkoopprogramma Persbericht - Gereglementeerde informatie Ieper, België – 9 juni 2025, 17.45 uur CET Naar aanleiding van het aandeleninkoopprogramma dat op 10 december 2024 werd aangekondigd, maakt Melexis bekend dat er 19.334 eigen aandelen ingekocht werden op Euronext Brussel tussen 2 en 6 june 2025. InkoopdatumAantal verworven aandelenGemiddelde prijs (€)Laagste prijs (€)Hoogste prijs (€)Aankoop bedrag (€)2/6/20255.00058,6058,0059,25292.9803/6/20255.00059,7157,8060,45298.5414/6/20255.00062,6861,3563,30313.4225/6/202533463,8663,6064,0021.3286/6/20254.0...
Melexis: update on the share buy-back program Press release - Regulated Information Ieper, Belgium – 9 June 2025, 17.45 hrs CET Further to the initiation of the share buy-back program announced on 10 December 2024, Melexis reports the purchase of 19,334 Melexis shares on Euronext Brussels in the period from 2 to 6 June 2025. Trade dateTotal shares purchasedAverage price (€)Min price (€)Max price (€)Buyback amount (€)2/6/20255,00058.6058.0059.25292,9803/6/20255,00059.7157.8060.45298,5414/6/20255,00062.6861.3563.30313,4225/6/202533463.8663.6064.0021,3286/6/20254,00064.7164.4065.00258,851T...
Today, we are publishing the automotive section of our 27th Tech Infrastructure Quarterly Bible. The Tech Bible is a must-read for any tech investor, as it summarizes the quarterly earnings reports from the over 140 companies we track, providing an update on our key perspectives and convictions. Auto semi revenues declined, reflecting the ongoing inventory correction. However, nearly all companies have now called the bottom. We expect strong sequential momentum through 2025, which should suppor...
Ageas: Reinsurance partnership with TRIGLAV, taking QS on Italian motor direct insurance Belgian Telecoms: Digi introduces a new mobile subscription at €3. Kinepolis: Box office in US/Canada up 76% YoY while France visitors were down 25%. NN Group & ASR: Dutch coalition collapse not affecting Dutch Pension Reform. SBM Offshore: Farewell Aseng after 13.5 years of service. Events Calendar
In this June update, we've made four adjustments to the KBC Securities Dynamic Top Pick List: 1.Merus (Removed – 27 May) was removed following the release of strong interim Phase 2 data at the ASCO 2025 conference. Its lead asset, petosemtamab, in combination with Keytruda, showed a 63% overall response rate in first-line treatment of head and neck cancer—significantly outperforming Keytruda monotherapy. The resulting share price surge validated our investment thesis. 2. Adyen (Removed) has de...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.